Aims: To study the antiandrogenic and antimineralocorticoid activity of drospirenone, a novel progestogen used as a component of combined oral contraceptive pill (COC) and compare it's clinical and biochemical effects with that of desogestrel, the most commonly used progestogenic component of COC.
Introduction
The oral contraceptive pill (OCP) is one of the most extensively studied medications ever prescribed. The health bene¿ ts are numerous and outweigh the risks of their use. Despite the ef¿ cacy and availability of OCP, many women who require continuing contraception, stop using it primarily because of tolerability issues including cycle control, weight gain, water retention, perimenstrual symptoms and hypertension 1, 2 . Most common type of OCP used is the combined monophasic preparation containing 30mcg of ethinyl estradiol and 150 mcg of desogestrel. Side effects due to the estrogen component are dose related. So, newer preparation of pills are formulated having lower dose of oestrogen but with equal contraceptive ef¿ cacy.
Importantly, the progestogenic component usually determines the overall metabolic and clinical effects, and therefore influences individual contraceptive choice 3 . As a consequence, ongoing clinical trials have focused on developing more selective progestogens that enhance the bene¿ cial (progestogenic) effects of the drug and reduce or eliminate the undesirable (mainly androgenic) effects like skin and hair changes, adverse effect on lipid pro¿ le 4 .
In 2001, FDA approved a new OCP that contains Drospirenone (DRSP) a novel progestin which is an analogue of spironolactone. It has pharmacological profile similar to Progesterone; particularly its antimineralocorticoid effects. It thus counteracts estrogen mediated À uid retention allowing stable or slightly lowered body weight. It also has an antiandrogenic effect on skin, hair, weight, lipid pro¿ le and bene¿ cial effects on premenstrual symptoms 5 .
The aim of our study was to demonstrate the antiandrogenic and antimineralocorticoid benefits of drospirenone and to compare the changes in body weight, blood pressure, lipid pro¿ le, serum sodium and potassium level caused by drospirenone with desogestrel, widely used progesterone.
Methods
A prospective study was carried out in a tertiary medical Centre in eastern India from July2008 to June 2010. Two hundred women of 20-40 years age group attending the gynaecology outdoor for contraception or problems associated with polycystic ovarian disease, or those likely to be bene¿ tted by non contraceptive advantage of OCP were included in the study.
After ruling out any contraindications of hormonal contraceptives, 100 subjects were administered ethinyl estradiol (30mcg) / drospirenone (3mg) combination and were referred to as DRSP/EE Group and 100 subjects were prescribed low dose oral contraceptive pills containing 30mcg ethinyl estradiol and 150mcg of desogestrol and referred to as other OCP group. Prior to therapy, body weight, blood pressure, lipid pro¿ le, serum sodium and potassium levels were measured, and scoring of hirsutism was done according to FG Score. Other causes of hirsuitism were excluded. Each individual were given the drug for 6 cycles.
Subjects were asked to come back after 1st cycle and at completion of therapy. Clinical examination was done and the initial investigations were repeated.
Antiandrogenic effect of drospirenone was studied by observing changes in FG score and lipid pro¿ le of the patients. The antimineralocorticoid activity of DRSP was studied by noting improvements in body weight, perimenstrual symptoms and changes in the serum sodium and potassium level.
Results
In this study most cases belonged to the age group of 20 to 25 years (51%). Indication of prescribing the drugs in both groups is shown in table 1 and weight wise distribution of the cases are given in ¿ g 1. Fifty nine percent of the total subjects did not have any hirsutism. 36 subjects in DRSP/EE group and 34 in the other group had mild hirsutism and 6 subjects each in both groups showed moderate hirsutism. None of the subjects had severe degree of hirsutism
Side effects
Nausea was the commonest side effect in EE/DRSP group; 16% compared to 18% in other OCP group. Breast tenderness was seen in only 10% of subjects in DRSP/EE group as compared to 20% in other OCP group. Only 6% of subjects on DRSP/EE had bloating as compared to 16% on other OCPs. 4%of subjects in DRSP group reported of headache and irritability whereas the incidence of headache and irritability was 8% and 6%, respectively in the other OCP group.
In the DRSP/EE group 38(38%) patients showed no change in their body weight at the end of 6 treatment cycles. Rest 62(62%) showed a small decrease in their body weight (statistically insigni¿ cant). In the study group receiving other low dose OCP 52 subjects showed increase in body weight, 32 had no change, and 16 had weight loss.
None of the subjects in DRSP/EE group had any increase in their FG score. Sixty eight patients showed no change and the rest (32%) had a decrease in the FG score that is not clinically signi¿ cant. In the other OCP group most of the patients (70%), showed no change in their FG score, however it did not decrease in any of the cases. Thirty percent cases showed worsening of hirsutism clinically which is not statistically signi¿ cant.
Majority of women in the study population had Systolic Blood Pressure (SBP) in the range of >110-120 mm of Hg and diastolic blood pressure in the range of >60 to 70 mm of Hg. In the group receiving DRSP/EE, 44(44%) subjects showed a decrease in systolic blood pressure and 36(36%) subjects showed a decrease in diastolic blood pressure from baseline after completion of six cycles. None of the subjects showed any increase in blood pressure and all values were within normal limit. In the other OCP group none of the subjects At the beginning of the study, baseline serum sodium was in the range of 136-140mmol/litre (47%) and serum potassium level in the range of 3.5-4mmol/ litre. In the DRSP/EE group 86 subjects showed a decrease in the serum sodium level and rest 14 subjects had no change. All before and after values remained within normal limit. In the group administered other low dose OCPs 38 subjects showed no change in the serum sodium levels from the baseline and the rest 62 subjects showed a net gain in the serum sodium level ( Table 2 ). Both the groups showed a rise in mean serum potassium values after 6 cycles but the mean level remained within normal range. All these changes had insigni¿ cant p-values. 
Discussion
In our study, there was a decrease in mean body weight by 1.25% in the DRSP/EE group and increase in mean weight by 0.69% from baseline in the other OCP group. Similar results were obtained in a study by Oelkers W et al, though the results of both studies were not statistically signi¿ cant (6) . We also have found a statistically insigni¿ cant decrease in the FG score in 32% women in the DRSP/EE group and increase in none of them. No evidence of decrease in the FG score seen in any of the cases in other group whereas 30% of the subjects showed an increased value. Similar but statistically signi¿ cant decrease in FG score was also evident with drospirenone in studies by Pehlivanov B et al, Guido M et al and Batukan C et al 7, 8, 9 at 6th cycle onwards and was maintained at 12 th cycle. In few previous studies as well as in our study, a general trend towards reduction in both systolic and diastolic blood pressure in the DRSP/EE group have been demonstrated, although these changes were not clinically signi¿ cant at 6 months 6,10 .
This study showed that the subjects receiving DRSP/ EE either had no change in their serum sodium values or had statistically insigni¿ cant decrease in the values. This might be explained by the action of drospirenone on the renin angiotensin aldosterone system, thus preventing À uid and sodium retention in the body.
In the other OCP group, there was either an increase or no change in the serum sodium level. Probably because desogestrol does not counteract sodium and water retention caused by ethinyl estradiol. In a study by Oelker 6 et al no signi¿ cant change in serum sodium or potassium level occurred due to drospirenone /ethinyl estradiol or ethinyl estradiol/ levonorgesterol. Although more marked increase in aldosterone in the DRSP/ EE group reÀ ected a compensatory natriuretic action.
In this study serum triglyceride showed a slight and insigni¿ cant increase in both the groups, reÀ ecting the action of estrogen. Serum HDL-Cholesterol showed a signi¿ cant increase in both the groups which is a known metabolic effect of both the estrogen and progestogen 11 .
In the DRSP/EE group there was an insigni¿ cant decrease in serum LDL-cholesterol thus having a favourable impact on HDL-cholesterol/LDLcholesterol ratio as well as on cardiovascular system.
On the other hand in the other OCP group, LDLcholesterol showed a slight but non signi¿ cant increase from baseline after 6 cycles, due to androgenic effect of desogestrol. In an open label multicentre study of 326 women who received DRSP (3mg)/EE (30 gm) for 12 cycles total cholesterol, triglyceride, HDL and HDL/LDL ratio showed similar but signi¿ cant increase from baseline 12 .
Conclusion
The new progestin drospirenone has different pharmacological property and results in improved non contraceptive bene¿ ts and reduced side effects.
Its antimineralocorticoid activity prevents fluid retention, weight gain, bloating, rise in blood pressure and breast tenderness seen in some susceptible women with use of OCPs. Studies have also shown that it may produce a fall in both systolic and diastolic blood pressure. Drospirenone has an anti-androgenic effect at the receptor and enzymatic level, leading to reduction in appearance or worsening of hirsutism, oily skin and appearance of acne. These effect when seen with use other androgenic progestins is very distressing for women especially if they are young causing them to discontinue the pill.
Estrogen has a favourable effect on the lipid pro¿ le. Androgenic progestin attenuates this effect. Drospirenone being anti-androgenic, it decreases LDLcholesterol, increases HDL-Cholesterol and HDL/LDL ratio which reduces the atherogenicity of blood.
